1 / 6

Supplemental Figure 1

Supplemental Figure 1. Supplemental Figure 1: IL-10 production in positively or negatively selected B cells.

johnarce
Download Presentation

Supplemental Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Figure 1 Supplemental Figure 1: IL-10 production in positively or negatively selected B cells. B cells were isolated with un-touched (Untouched B cells) or anti-human CD19 (Positive selection) and treated with HIV-1 IIIB gp120 (named gp120), AZT+T20, Mock-treated or treated with HIVNL4-3. Alternatively, virus were treated with HIV-1 gp120 monoclonal antibody used at ratio 1:5 (anti-gp120 : HIVNL4-3) or with anti-human CD40L (anti-CD40L : HIVNL4-3) for 1h before adding the virus onto cells. % of IL-10-producing cells was followed by flow cytometry . Average + SEM of 2 experiments (Untouched B-cell) or 3 experiments (Positive selection).

  2. Supplemental Figure 2 A B * * Supplemental Figure 2: TGFβ1 and IL-12 production. B cells were treated with CD40L/IL-4 ; HIV; CD40L/IL-4/HIV; CpG/CD40L/LPS and CpG/CD40L/LPS/HIV for 48h. Cells were also Mock-treated (Mock) or not treated (NT). TGFβ1 (A) and IL-12 (B) were quantified in supernatant of cell cultures. Average + SEM of 4 experiments. *=p<0.05 when comparing Mock-treated condition versus treated condition.

  3. Supplemental Figure 3 B Activated EC+ CpG/CD40L/LPS/HIV B cells Activated EC+ CpG/CD40L/LPS B cells Activated EC+ CD40L/IL-4/HIV B cells Activated EC+ CD40L/IL-4 B cells Activated EC+ Mock B cells Activated EC+ NT B cells Activated EC+ HIV B cells Non-activated EC Activated EC count CD4 CD8 CFSE A B

  4. Supplemental Figure 3: Flow cytometry gates and inhibition of the EC proliferation experiment. Proliferation of autologous effector cells (EC) treated with CFSE and co-cultured with NT or treated-B cells (ratio Treated B-cell:EC of 2:1) at day 3 post-co-culture. (A) Viable cells were analyzed for CD4 or CD8 expression. (B) Histograms of CD4+ and CD8+ T-cell proliferation analyzed by flow cytometry following the loss of CFSE fluorescence. One representative experiment out of 5 is showed. Numbers represent the percentage of proliferation for CD4+ (CD4p) or CD8+ (CD8p) T cells. NT: non treated cells.

  5. Supplemental Figure 4 Activated EC+ CpG/CD40L/LPS/HIV B cells Activated EC+ CpG/CD40L/LpS B cells Activated EC+ CD40L/IL-4/HIV B cells Activated EC+ CD40L/IL-4 B cells Activated EC+ Mock B cells Activated EC+ NT B cells Non-activated EC Activated EC+ HIV B cells Activated EC count CD4 CD8 TNF-α

  6. Supplemental Figure 4: Flow cytometry gates and the inhibition of the EC TNFα expression experiment. Intracellular TNFα expression of autologous effector cells (EC) co-cultured with non treated (NT) or treated-B cells (ratio Treated B-cell:EC of 2:1) at day 3 post-co-culture. (A) Viable cells were analyzed for CD4 or CD8 expression. (B) Histograms of intracellular TNFα expression analyzed by flow cytometry. One representative experiment out of 6 is showed. Numbers represent the % of TNFα expression in CD4+ (CD4t) or CD8+ (CD8t) T cells .

More Related